Consensus Review of the Treatment of Cardiovascular Disease in People With Hemophilia A and B

Victor A. Ferraris, MD, PhD,* Leonard I. Boral, MD, MBA,† Alice J. Cohen, MD,‡ Susan S. Smyth, MD, PhD,§ and Gilbert C. White, II, MD||

Abstract: With advances in care, increasing numbers of people with hemophilia (PWH) achieve near-normal life expectancies and present with typical age-related cardiovascular conditions. Evidence-based guidelines for medical or surgical management of cardiovascular conditions in individuals with hemophilia are limited. Published recommendations exist for the management of some common cardiovascular conditions (eg, ischemic heart disease, atrial fibrillation), but identifying optimal strategies for anticoagulant or antithrombotic therapy constitutes the primary challenge of managing nonoperative cardiovascular disease (CVD) in PWH. In general, as long as factor concentrates or other hemostatic therapies maintain adequate hemostasis, the recommended medical and surgical management of CVD in PWH parallels that in individuals without hemophilia. The presence of factor inhibitors complicates hemophilia management. Published outcomes of CVD treatment in PWH are similar to those in the general population. Specific knowledge about factor replacement, factor inhibitors, and disease-specific treatment distinguishes the cardiovascular care of PWH from similar care of individuals without this rare bleeding disorder. Furthermore, a multidisciplinary approach incorporating a hematologist with an onsite coagulation laboratory, ideally associated with a hemophilia treatment center, is integral to the management of CVD in PWH.

Key Words: hemophilia, cardiovascular diseases, cardiac surgery, atherosclerosis, atrial fibrillation

(Original Article Review in 2015;23: 53–68)

Hemophilia A and B (hereafter collectively referred to as “hemophilia”) encompass congenital deficiencies of the intrinsic pathway coagulation factors VIII (FVIII) and IX (FIX), respectively, with a variable risk for bleeding based on the type of hemophilia and the extent of factor deficiency. This risk for bleeding may complicate both medical and surgical management of congenital and acquired cardiovascular conditions in people with hemophilia (PWH), particularly those who are receiving anticoagulant or antithrombotic treatment or who require invasive measures for palliation or correction of a cardiovascular lesion.

PWH who receive repeated doses of factor as replacement may develop coagulation factor inhibitors that complicate the management of cardiovascular disease (CVD). Limited experience and a lack of evidence-based guidelines pose further challenges in the management of cardiovascular conditions in this population. As PWH are now achieving near-normal life expectancies due to advances in the management of their underlying disease, health care providers expect an increasing number of PWH presenting with typical cardiovascular conditions of the aging population.

This article examines the epidemiology and etiology of acquired CVD in PWH; summarizes the management of hemophilia, including hemostatic therapeutic options; and reviews the existing evidence and recommendations for managing various nonoperative and operative cardiovascular conditions in this unique population. Because of the specialized care required by these individuals, a multidisciplinary group of authors contributed to this work and provided a consensus set of recommendations for treating cardiovascular conditions in PWH. Other rare nonhemophilia congenital bleeding disorders lack data regarding CVD and are not considered in this consensus statement.

We performed a search of multiple sources to identify articles describing diagnoses and management of CVD in PWH. Table 1 lists the search categories and criteria used.

UNDERLYING DISEASE COURSE, LIFE EXPECTANCY, AND AGE-RELATED CARDIOVASCULAR DISEASE IN HEMOPHILIA

The clinical severity and bleeding risk in PWH depends on factor levels. Mild hemophilia is commonly defined by FVIII or FIX activity levels of greater than 5% (>0.05 IU/ml), constitutes 30–40% of hemophilia cases, and typically presents with bleeding episodes after hematologic stress (ie, surgery, vaginal delivery, or trauma).1 Moderate hemophilia is defined by FVIII or FIX activity levels between 1% and 5% (0.01–0.05 IU/ml), occurs in 10% of PWH, and presents with spontaneous bleeds or bleeding after operation or trauma.1 Severe hemophilia is characterized by FVIII or FIX activity levels of less than 1% (<0.01 IU/ml), occurs in 50% of PWH, and presents with spontaneous bleeding into joints and muscles and life-threatening (eg, intracranial) hemorrhage.1 Although the majority of cases of hemophilia A and B are inherited (X-linked recessive), about one third of PWH who are newly diagnosed have spontaneous mutations without any family history of bleeding.2

Complications may develop because of factor replacement therapy in PWH. Importantly, up to one third of individuals with severe hemophilia A develop alloantibody inhibitors to FVIII after replacement therapy.3 The incidence of FIX inhibitor development is much lower in individuals with hemophilia B (1–6%).4 In hemophilia A, formation of FVIII alloantibodies is highest in individuals...
with certain gene mutations, specifically intron 22 inversions, large deletions, and nonsense mutations. PWH transfused with plasma-derived factor replacement products risk development of transfusion-related viral infections, including human immunodeficiency virus (HIV) and hepatitis C virus (HCV). As of 2002, the first Multicenter Hemophilia Cohort Study found that concomitant HIV infection was present in more than half of HCV-seropositive PWH included in the study. However, adoption of viral inactivation methods beginning in the mid-1980s substantially reduced the risk of HIV and HCV transmission via plasma-derived FVIII and FIX concentrates.

Due to advances in care, including comprehensive management in hemophilia treatment centers (HTCs), primary and secondary prophylaxis, and improvements in factor replacement therapies, PWH achieve near-normal life expectancies. Since the 1990s, life expectancies in high-income countries exceed 70 years in HIV-negative men with hemophilia. PWH with severe disease (very low FVIII or FIX levels), including those with HIV specifically, achieve lower life expectancies by approximately 10 years. PWH with factor inhibitors previously had a reduced life expectancy; however, an analysis from the 1990s showed that the presence of inhibitors did not increase mortality rates in individuals with severe hemophilia with or without HIV. An analysis of the Nationwide Inpatient Sample from 2007 found that the median age at death of hospitalized PWH in the United States (US) was 68 years, compared to 72 years in hospitalized individuals without hemophilia. Leading causes of death in PWH included typical age-related conditions like sepsis (38%), congestive heart failure (30%), respiratory failure (28%), and pneumonia (25%), rather than intracranial hemorrhage or HIV (16%). As the population of PWH ages, health care providers face increasing numbers of PWH presenting with typical age-related comorbidities, including ischemic heart disease (IHD), other atherosclerotic conditions, and degenerative valve disease.

The literature supporting any protective effect of hemophilia against IHD is conflicting. Some studies suggest that mortality from IHD is lower in PWH than in the general population, presumably due to a “hypocoagulable” state that prevents thrombus formation and coronary arterial occlusion after rupture of an atherosclerotic plaque. Others suggest that increased levels of various coagulation proteins, including FVIII and FIX, predispose affected individuals to atherogenesis; however, reduced FVIII and FIX levels in PWH do not seem to ultimately protect against the development of atherosclerosis. In fact, current consensus warns that the prevalence of atherogenesis and endothelial dysfunction is similar between PWH and the general population. The extent of these abnormalities correlates with traditional cardiovascular risk factors rather than hemophilia severity. When compared with a cohort of hospitalized individuals without hemophilia, hospitalized PWH had similar rates of angina, myocardial infarction (MI), and cardiovascular risk factors such as hypertension, diabetes mellitus (DM), obesity, and hyperlipidemia.

Although the risk of coronary artery thrombus formation may be low in PWH, a cautionary note exists. Other events such as plaque rupture with atheroemboli, coronary vasospasm, or intra-plaque hemorrhage may lead to coronary events in PWH with coronary atherosclerosis. Isolated case reports suggest that supernormal FVIII infusions, like those given for factor replacement in PWH before an invasive procedure, can induce coronary thrombosis, as may other hemostatic therapies. The presence of other underlying cardiovascular risk factors may contribute to such events. PWH having procedures that typically employ anticoagulation such as cardiac operations or percutaneous coronary interventions (PCIs), require special considerations. Older patients with milder forms of hemophilia (mild or moderate factor level deficiencies) may be at particular thrombotic risk from factor replacement. These individuals require a delicate balance between anticoagulation or antiplatelet drugs and factor replacement.

PWH are susceptible to the same cardiovascular risk factors as individuals without hemophilia, and even more so to certain traditional risk factors such as hypertension and obesity related to limited mobility from arthropathy. In a cohort of more than 700 PWH from the Netherlands and United Kingdom, the predicted 10-year risk of fatal MI or stroke was significantly higher (8.9%) than in the general population (6.7%), based solely on typical factors determining cardiovascular risk (including age, blood pressure, total/high-density lipoprotein cholesterol, body mass index, and smoking or DM history). A recent 5-year cross-sectional study of PWH older than age 35 in the US found that PWH had twice the lifetime prevalence of coronary artery disease (CAD), stroke, and MI compared to nonHispanic white men overall. Nearly 40% of PWH in this study had 2 or more traditional risk factors for CVD. In a review of 36 cases of confirmed MI in PWH, 11 PWH had 1 or more acquired risk factors for CVD, including smoking, obesity, hypertension, and immobility. Systemic hemostatic therapies contributed to mortality in more than half (n = 22) of the PWH with MI. Other unique risk factors predisposing to IHD in PWH include type and severity of hemophilia (with hemophilia B and mild disease being more likely among PWH with IHD in 1 cohort), dyslipidemia, DM, and in PWH with HIV, hypertension from antiretroviral treatments.

Table 1. Search Categories and Criteria Used to Obtain Relevant Evidence About Cardiovascular Disease in People With Hemophilia

| Search Categories | Criteria |
|-------------------|----------|
| Language          | English only |
| Years covered by literature search | 1980–2013 |
| MESH search topics used in PubMed search | Hemophilia, cardiac disease, cardiac surgery, coronary artery bypass, factor inhibitors |
| Specific search subtopics | • Guidelines or consensus statements for treatment of PWH with CVD  
• Review articles  
• Stroke risk in PWH with atrial fibrillation  
• Use of antiplatelet drugs in PWH  
• Case reports of operative cardiac procedures in PWH  
• Article bibliographies to find reports of treatment of PWH (mostly surgical patients) not in traditional peer-reviewed journals  
• Web-based reports  
• Government publications  
• Publications in nonPubMed indexed journals  
• PhD dissertations |

CVD indicates cardiovascular disease; PWH, people with hemophilia.

The results of this search did not yield any relevant sources for inclusion in this article.
As PWH achieve longer life expectancies, their exposure to various cardiovascular risk factors increases. As a result, it is reasonable to expect greater numbers of PWH presenting with atherosclerotic disease in the future. Existing data already show a trend toward an increasing prevalence of IHD among PWH with increasing age, similar to the general population. Among more than 3000 PWH from the US in the late 1990s, the prevalence of IHD ranged from 0.05% in those younger than 30 years to 15.2% in those older than 60 years. Similarly, there will likely be an increase in PWH presenting with other atherosclerotic conditions such as carotid occlusive disease and peripheral arterial disease (PAD), and other age-related cardiovascular conditions. In addition, PWH are susceptible to other acquired cardiovascular conditions, regardless of age: for example, PWH with late-stage HIV infection may be susceptible to acquired dilated cardiomyopathy.31

**STANDARD HEMOPHILIA MANAGEMENT**

Familiarity with the general management of hemophilia, particularly the options for treatment or prevention of bleeding, is an essential starting point for understanding the particular aspects of treating PWH who also have CVD. Replacement of the deficient factor using specific factor concentrates is a mainstay of therapy, especially in PWH with active bleeding or in those requiring operative interventions. Treatment for bleeding episodes consists of both on-demand regimens (ie, at onset of discrete bleeding episodes) and prophylactic regimens. In the latter, replacement factor is given on a scheduled basis with the intent of preventing bleeding, especially hemarthroses, a particularly disabling bleeding-related complication in PWH.32 Administration of factor concentrates before, during, and after surgical or other invasive procedures limits bleeding, with the administered amounts of factor concentrates depending on hemophilia type and severity and the risk for bleeding associated with the procedure. Nonspecific blood products such as fresh frozen plasma (FFP) or cryoprecipitate contain relatively small amounts of hemophilia factors and are not viral inactivated.33 As a result, administration of these nonspecific products risks disease transmission and may prove insufficient to control or prevent bleeding in many PWH who have severe bleeding episodes.

**Hemophilia Factor Replacement**

Options for factor replacement include plasma-derived and recombinant products (Table 2).33,34 The screening of blood donors and harvested blood products along with adoption of viral inactivation methods has dramatically improved the safety of human plasma-derived factor concentrates.35 Specifically, there have been no reports of HIV or HCV transmission from clotting factor concentrates since 1986 and 1997, respectively.36 Still, concerns remain regarding the transmission of other pathogens, including nonenveloped viruses such as the parvoviruses and hepatitis A, or prions (variant Creutzfeld-Jakob disease).35,37,38

Recombinant products developed in the wake of the 1980s HIV epidemic significantly reduce the risk of transmitting blood-borne pathogens.33 The newest generation of recombinant products lack any human proteins in any of the production processes.33 Accordingly, the Medical Advisory and Scientific Council of the National Hemophilia Foundation recommends recombinant factor concentrates as the treatment of choice for bleeding control and for surgical coverage in individuals with hemophilia A or B.33 Consultation with a hematologist facilitates the choice of replacement product. Ultimately, the choice depends on several variables in addition to the potential for viral transmission, including availability, cost, and prior product exposure.35 Replacement factor dosing requires achievement of a pre-specified percentage of normal factor activity that varies based on the specific indication (eg, hemostatic coverage for minor vs major surgery). For example, immediately before major operations, correction of factor activity level to 80–100% of normal is preferred to optimize hemostasis.38 Individuals with mild hemophilia (ie, with factor activity >5% of normal) require lesser amounts of factor concentrate than do those with severe hemophilia (ie, with factor activity level <1% of normal) and in some cases may not require any factor correction at all.

**Complications of Factor Replacement**

Currently, the most serious and costly complication of factor replacement therapy is the development of alloantibodies, or inhibitors, to the infused factor.49 Inhibitors develop in approximately 20–30% of patients with severe hemophilia A and in 1–6% of those with severe hemophilia B.5 Individuals with mild hemophilia typically have a low risk for developing inhibitors, but they are susceptible to developing inhibitors after receiving large amounts of factor concentrates for a surgical procedure, especially if they have had no previous exposure to exogenous factor replacement.49 The presence of inhibitors typically makes factor replacement ineffective, complicating the management of bleeding events and coverage for surgical or other invasive procedures.

In PWH who develop inhibitors, bypassing agents are generally the first-line systemic therapy for hemostatic coverage, particularly for high-titer (>5 Bethesda units/mL) inhibitors.48 These agents bypass the role of the inhibited factor in the coagulation cascade (Table 2). The bypassing agents consist of both recombinant activated factor VII (rFVIIa; NovoSeven RT [Coagulation Factor VIIa (Recombinant)], Novo Nordisk Inc., Bagsvaerd, Denmark) and a viral-inactivated, plasma-derived activated prothrombin complex concentrate (pd-aPCC) containing factors II, IX, and X in mostly nonactivated forms and factor VII in the activated form [FEIBA NF (Anti-Inhibitor Coagulant Complex), Nanofiltered and Vapor Heated, Baxter Healthcare Corporation, Westlake Village, CA].

Concerns with the use of bypassing agents in the management of PWH with inhibitors include the lack of laboratory testing to predict efficacy48 and a risk of thrombotic events. Case reports describe MI and disseminated intravascular coagulation in individuals with concurrent liver disease, those of advanced age, and those receiving higher-than-recommended amounts of pd-aPCC.43–45 However, in a postmarketing survey of the use of FEIBA (pd-aPCC) in individuals with inhibitors, the incidence of thrombosis over 10 years was very low, with only 16 events occurring in the equivalent of 395,000 infusions.50 Likewise, the incidence of thromboembolic events that were possibly or probably attributable to rFVIIa in clinical studies within approved indications for PWH with inhibitors was 0.20%.47

Although not relevant to the hemophilia population discussed here, the off-label use of rFVIIa outside of the approved indications is associated with higher rates of thromboembolic events than in placebo controlled trials.48,49 Because pd-aPCC is used virtually exclusively in PWH with inhibitors, comparable data regarding the risk of thrombotic events with off-label use of pd-aPCC are not available. Ultimately, in PWH with inhibitors who require hemostatic coverage, the risk for thromboembolism must be weighed against the risk for bleeding on an individualized basis.

**Nonfactor Replacement Therapies for People With Hemophilia**

In some instances, administration of nonfactor replacement therapies occurs in lieu of, or in addition to, factor replacement products for surgical coverage or for management of perioperative bleeding (Table 2). Such therapies avoid the potential risks and costs associated with factor replacement.48 PWH may benefit from either of 2 types of nonfactor replacement therapy: desmopressin or antifibrinolytic agents. Desmopressin is effective in mild hemophilia.
| Type of Hemophilia | Recombinant Factors | Plasma-Derived Concentrates | Bypassing Agents | Other Therapies |
|-------------------|---------------------|-----------------------------|------------------|----------------|
| **Hemophilia A**  | rFVIII recommended treatment of choice, especially in PwH not previously exposed to plasma products<sup>33,34</sup> | Plasma-derived FVIII concentrates | (Not indicated in the absence of inhibitors) | Mobilizes FVIII stores from endothelial cells<sup>34</sup> |
|                   | • Lower risk for viral transmission compared with plasma-derived products<sup>33,34</sup> | • Virally inactivated, in addition to improved screening of plasma donors<sup>*</sup> | • Multiple doses not effective because stores of FVIII are depleted<sup>3</sup> and not replenished for 1–2 weeks | TXA indicated for short-term use to reduce/prevent bleeding and reduce the need for replacement therapy during/after dental extraction<sup>6</sup> |
|                   | • No animal- or human-derived proteins used in the manufacturing of newest-generation products | | • Indicated in lieu of factor replacement for treatment/prevention of bleeding in mild hemophilia A (FVIII activity >5%)<sup>33,34,52</sup> | • Adjunctive use described in the setting of nondental surgeries as well<sup>6</sup> |
|                   | • Greater cost relative to plasma-derived concentrates | | • Should not be used in pregnant women or children aged <2 years<sup>33</sup> | • Monitor for thromboembolic complications, particularly when used with other hemostatic agents or in persons at risk (eg, older adults, those with known thrombophilia) |

**Hemophilia B**

| Recombinant FIX concentrate† recommended treatment of choice, especially in PwH not previously exposed to plasma products<sup>33,34</sup> | Plasma-derived FIX concentrates‡ | (Not indicated in the absence of inhibitors) | | |
|-------------------|---------------------|-----------------------------|------------------|----------------|
|                   | • Lower risk for viral transmission compared with plasma-derived products<sup>33,34</sup> | • Virally inactivated, in addition to improved screening of plasma donors and supply | • TXA indicated for short-term use to reduce/prevent bleeding and reduce the need for replacement therapy during/after dental extraction<sup>6</sup> | • Adjunctive use described in the setting of nondental surgeries as well<sup>6</sup> |
|                   | • Product available in the US is third-generation (ie, no animal- or human-derived proteins used in the manufacturing process) | | • Monitor for thromboembolic complications | • Monitor for thromboembolic complications |
|                   | • Greater cost relative to plasma-derived concentrates | | | |

**Hemophilia A or B with inhibitors**

| May be able to use recombinant FVIII or FIX if inhibitor level is low (<5 BU/ml) | May be able to use plasma-derived FVIII or FIX if inhibitor level is low (<5 BU/ml) | Bypassing agents—rFVIIa (NovoSeven RT§) and pd-aPCC (FEIBA NF¶) effective and safe for hemostatic coverage for major and minor surgery in PwH with inhibitors<sup>41</sup> | | |
|-------------------|---------------------|------------------|------------------|----------------|
|                   | • First-line treatment, especially when inhibitor titer exceeds 5 BU/mL<sup>41</sup> | • rFVIIa is generally used in individuals with hemophilia B<sup>41</sup> | • TXA indicated for short-term use to reduce/prevent bleeding and reduce the need for replacement therapy during/after dental extraction<sup>6</sup> | • Monitor for thromboembolic complications, particularly when using bypassing agents or factor concentrates |
|                   | • Features impacting choice of bypassing agent include availability, prior patient response, and cost<sup>33,41</sup> | | | |
|                   | • Monitor for thromboembolic complications | | | |

**FIX** indicates factor IX; FVIII, factor VIII; PWH, people with hemophilia; pd-aPCC, plasma-derived activated prothrombin complex concentrate; rFVIIa, recombinant activated factor VII; TXA, tranexamic acid; US, United States.

<sup>*Licensed plasma-derived FVIII concentrates in the US include Hemofil M (Baxter Healthcare Corporation; Westlake Village, CA) and Monoclate-P (CSL Behring LLC; Kankakee, IL).
†BeneFIx (Wyeth Pharmaceuticals Inc., Philadelphia, PA) is the only licensed recombinant FIX concentrate in the US.
‡Licensed plasma-derived FIX concentrates in the US include AlphaNine SD (Grifols Biologicals Inc., Los Angeles, CA) and Mononine (CSL Behring LLC; Kankakee, IL).
§NovoSeven RT (Novo Nordisk A/S, Bagsvaerd, Denmark).
¶FEIBA NF (Baxter Healthcare Corporation; Westlake Village, CA).**
A and usually allows for avoidance of FVIII concentrates. Desmopressin reduces blood loss and red blood cell transfusion requirements in select patients without bleeding disorders who experience bleeding after open-heart procedures. The antifibrinolytics, tranexamic acid and epsilon-aminocaproic acid, act as adjuncts in PWH who require operations. Both desmopressin and antifibrinolytics may predispose PWH to myocardial ischemia, so, like factor replacement therapies, they should be used with caution in PWH with potential IHD. This includes those individuals with traditional cardiovascular risk factors. Desmopressin may be particularly thrombogenic in individuals with underlying CAD as it induces release of both FVIII and von Willebrand factor from endothelial cell granules.

**GENERAL PRINCIPLES IN THE MANAGEMENT OF CARDIOVASCULAR DISEASE IN PEOPLE WITH HEMOPHILIA**

The management of common cardiovascular conditions poses unique challenges in PWH, particularly in individuals requiring anticoagulant and antiplatelet therapy, or in those requiring invasive procedures. The presence of factor inhibitors further complicates management. Because of the lack of evidence-based guidelines, recommendations for the management of CVD in PWH are based on expert opinion, or on anecdotal experience from both cardiac and noncardiac procedures, mostly in patients without inhibitors. Given the relatively limited experience with managing CVD in this population, consultation with a hematologist who has experience in hemophilia management is paramount, particularly for assistance with navigating the fine balance between antithrombotic and hemostatic therapy required for many of these conditions. Furthermore, invasive cardiac procedures in PWH—particularly those with inhibitors—pose an extremely high-risk situation and require infrastructure and resources specifically aimed at treating PWH. The optimal setting for such procedures is a facility designated as an HTC, where all necessary ancillary services (eg, laboratory, blood bank, pharmacy), full-spectrum resources (eg, factor concentrates and other hemostatic therapies), and medical and surgical expertise are available.

**NONOPERATIVE CARDIOVASCULAR CONDITIONS**

**Atrial Fibrillation and Other Cardiac Dysrhythmias**

Nonvalvular atrial fibrillation (AF) is a common age-related cardiovascular condition that often requires antithrombotic therapy to prevent associated thromboembolic events, particularly stroke. The decision to initiate antithrombotic therapy is normally based on the projected risk for stroke as determined by a risk scoring system: either the CHADS score or the increasingly used CHA2DS2-VASc score. The acronyms reflect risk factors for thromboembolic complications (congestive heart failure, hypertension, age ≥75 years, DM, stroke, vascular disease history) and their relative weight in the calculation of the score (ie, 2 points given for prior stroke or transient ischemic attack). The CHA2DS2-VASc score modifies this calculation to include age (0–2 points for age 65–74, 1 point for age ≥75) and provides better stratification of risk. Neither scoring system has been studied extensively in PWH.

PWH who develop AF are not immune to thromboembolic complications; therefore, in high-risk cases, antithrombotic prophylaxis may be warranted, provided sufficient baseline factor levels are assured. There are no clinical trial data to support recommendations for antithrombotic therapy in PWH; therefore, therapy should be individualized, taking the comparative risks for bleeding versus thromboembolic complications into account. Whereas, in the general population, antithrombotic therapy is recommended for individuals at intermediate risk for stroke (CHADS2 or CHA2DS2-VASc score = 1), a higher threshold (CHADS2 ≥2) is proposed for initiating antithrombotic therapy in PWH. Mannucci et al provided an algorithm for managing antithrombotic therapy in PWH with AF (Fig. 1). However, several important changes have occurred in the options and recommendations for antithrombotic therapy for AF in the general population in the interim, including the recognition that aspirin alone does not sufficiently protect against thromboembolism in AF and the introduction of left atrial (LA) appendage occlusion devices. Pharmacologic options for antithrombotic therapy in PWH at lower risk for bleeding (ie, those with baseline factor levels ≤50% and those with severe hemophilia who are on clotting factor prophylaxis) include oral anticoagulants and antiplatelet agents (Table 3). Oral anticoagulant options include the vitamin K antagonist warfarin, which should be titrated to achieve an INR of 2.0–3.0, and the new oral anticoagulants, such as direct thrombin or activated factor X inhibitors. New oral anticoagulants offer the benefits of shorter half-lives and lower bleeding risk than warfarin but have no specific antidotes and evidence of their use in PWH with AF is lacking. Oral anticoagulants offer better protection against stroke in AF than do antiplatelet agents, with a comparable risk for bleeding complications. In cases in which antiplatelet therapy is used, dual therapy incorporating both aspirin and clopidogrel is advised (Table 3), because the reduction in stroke risk imparted by aspirin alone is only moderate at best.

Mechanical interventions such as LA appendage occlusion or exclusion may alternatively be used to limit the duration of antithrombotic therapy in PWH with AF (Table 3). LA appendage occlusion devices reduce long-term risk of thromboembolism in AF, albeit with a trade-off of potential periprocedural complications. LA appendage occlusion may become the preferred strategy in PWH, especially those with factor levels ≤50%. This procedure has been described in a man with mild hemophilia A (FVIII level of 8%), allowing for a reduction of antithrombotic pharmacotherapy to a total of 6 weeks. Implantation of a LA appendage occlusion device should be done at an experienced center with a low complication rate. Antithrombotic prophylaxis is not recommended in PWH with inhibitors and AF given the heightened risk for bleeding and the difficulty in treating any bleeding episodes that might occur in this subgroup of PWH.

If cardioversion is elected, no antithrombotic therapy is needed before or after the procedure for AF of less than 48 hours duration. In PWH presenting with AF of longer duration, a transesophageal echocardiogram performed before cardioversion identifies periprocedural stroke risk related to the presence or absence of an LA thrombus. The absence of an LA thrombus permits avoidance of anticoagulation (and the attendant bleeding risk) in PWH before cardioversion. Cardioversion of AF requires anticoagulation with therapeutic doses of unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) during the procedure and for a period of 5 days thereafter (Table 3). PWH without inhibitors undergoing cardioversion simultaneously require factor replacement with either recombinant or plasma-derived FVIII or FIX, maintaining a trough factor activity level of around 80%. After discontinuation of periprocedural anticoagulation with UFH or LMWH, an additional 4 weeks of anticoagulation with a vitamin K antagonist is recommended, targeting an INR of 2.5. During this time, PWH should receive factor concentrates to maintain trough factor levels of 30%. Upon completion of this 4-week period of anticoagulation, PWH who remain in sinus rhythm convert to antithrombotic therapy based on basal factor level activity and stroke risk as outlined in Figure 1. Specific recommendations exist for the management of AF in PWH with inhibitors. Because of the use of anticoagulants and bypassing agents for bleeding prophylaxis, respectively, PWH with inhibitors who require anticoagulation for AF are at increased risk for both bleeding and thrombosis.
Coronary Artery and Ischemic Heart Disease

As in the general population, efforts in PWH focus on prevention of CAD when possible. Such efforts include screening adults with hemophilia for traditional cardiovascular risk factors after the age of 40 years, especially for hypertension and for obesity in PWH with arthropathy. Data suggest that screening and intervention for these traditional risk factors are currently suboptimal in PWH. Aggressive management of individual cardiovascular risk factors with appropriate medications and lifestyle modifications may allow for deferment of invasive interventions and antiplatelet medications in PWH with symptomatic CAD, especially those with inhibitors. Whether the benefits of low-dose aspirin prophylaxis for cardiovascular events outweigh the potential risk for bleeding in PWH is uncertain. Because of the bleeding risk, prophylactic low-dose aspirin therapy in PWH is currently not recommended as a rule. Chest pain syndromes may indicate myocardial ischemia in PWH, especially in those PWH with cardiovascular risk factors or when pain occurs after administration of factor replacement or bypassing agents.

Evidence-based guidelines for the treatment of IHD in PWH are lacking, but published recommendations are available, including institutional guidelines from the Netherlands. In general, the recommended management of IHD in PWH parallels that in people without hemophilia and reflects the primary clinical manifestation of IHD [ie, stable angina vs an acute coronary syndrome (ACS)], with factor replacement as needed to maintain adequate factor levels (Fig. 2, Table 3). Specific recommendations for PWH with inhibitors do not exist, and published anecdotal experience with the management of IHD in this population is extremely limited.

In all forms of IHD, antiplatelet or antithrombotic pharmacotherapy is a mainstay of treatment. In PWH, the provision of antiplatelet or antithrombotic therapy requires concomitant maintenance of minimal factor levels to reduce bleeding risk (Fig. 2, Table 3). Some PWH (especially with mild hemophilia) achieve recommended trough factor levels on their own without ongoing factor correction. In PWH with moderate or severe disease who require long-term aspirin therapy, 1 source recommends concomitant factor replacement initially, followed by bolus or continuous factor infusion as needed for bleeding complications thereafter. Managing traditional cardiovascular risk factors is particularly important in PWH with severe disease who cannot receive antiplatelet agents, including those who are not maintained on factor prophylaxis.
Recent articles summarize the “real-life” management and outcomes of ACS in PWH, including those managed with PCI. 63,64 PCI is primarily indicated in cases of ST-segment elevation myocardial infarction (STEMI) presenting within 12 hours (Fig. 2) and in certain high-risk non-STEMI patients. 6,55 Prospective evaluation of the previously mentioned Dutch guidelines support the recommendations for PCI for STEMI, 46 albeit in a small number of PWH, none of whom had severe hemophilia or inhibitors at the time of their procedures. There are several important considerations for performing PCI in PWH. Radial artery access is optimal in lieu of femoral access, especially in PWH with inhibitors. 65,66,81 A recent study found that selected individuals who underwent PCI for acute MI via the radial route had significantly lower bleeding rates, vascular complications, and mortality at 2 years compared with those who underwent PCI via the femoral route. 84 However, many publications document catheterization via the femoral route in PWH with negligible complications. 85,86 In cases where femoral access is used, a vessel closure device may reduce local bleeding complications. 86

In PWH who require stenting, a bare metal stent (BMS) facilitates a shorter duration of dual antiplatelet therapy (typically 1 month) compared with a drug-eluting stent (DES, up to 12 months). 63,65 A novel BMS under clinical development designed to enhance endothelialization by “recruitment” of endothelial progenitor cells [the Genous-R stent (OrbusNeich Medical Technologies, Fort Lauderdale, FL)] may allow an even shorter (ie, approximately 2 weeks) duration of dual antiplatelet therapy 47 in PWH. 88 Although the risk for restenosis in PWH is not known, 63 expert consensus suggests that the risk of prolonged dual antiplatelet therapy outweighs any benefit that a DES offers in terms of a reduced risk for restenosis. 63 Because of the limited ability of DESs to reduce mortality or reduce recurrent MI compared with BMSs, consensus recommendations suggest that only special circumstances like symptomatic restenosis or high risk for restenosis justify the use of DESs in PWH. 63,65 PWH with mild disease (specifically, factor levels exceeding 25%) are good candidates for DES in ACSs, as they may not require factor replacement for the duration of dual antiplatelet therapy. 63,65 Newer-generation DESs may permit shorter (ie, <6-month) periods of dual antiplatelet therapy 63,65 but experience in PWH is nonexistent.

In general, the regimen for antithrombotic therapy during and after PCI mirrors that recommended for PWH presenting with other ACSs; however, PWH undergoing PCI should additionally receive glycoprotein IIb/IIa inhibitors in the 12 hours after PCI (Fig. 2). 6,65 The short-acting direct thrombin inhibitor bivalirudin was used in lieu of UFH during successful PCI in 4 PWH described in the literature; 3 of these individuals had severe hemophilia. 83,89–91 Pretreatment with antiplatelet agents is recommended in the general population before PCI. 92 In contrast, consensus suggests deferring antplatelet therapy in PWH before possible PCI to limit bleeding events, 93 especially in the minority who may require urgent operative coronary revascularization. This recommendation is somewhat controversial because withholding antplatelet therapy in planned PCI risks the development of thrombi during PCI in PWH, especially when factor replacement is administered. 93 To avoid the burden and costs related to ongoing cloting factor correction, the recommended duration of dual antplatelet therapy in PWH is 1 month. 63 This recommendation coincides with general guidelines for the minimal duration of dual antplatelet therapy after placement of a BMS, the preferred stent for PWH with significant symptomatic coronary obstruction. 63

---

Table 3. Management Suggestions for Nonoperative Cardiovascular Disease in People With Hemophilia*

| Cardiovascular Condition | Antithrombotic Therapy | Hemostatic Therapy |
|-------------------------|------------------------|-------------------|
| Atrial fibrillation (nonvalvular) | Therapeutic doses of UFH or LMWH × 5 days, then warfarin × 4 weeks (target INR 2.5), then low-dose ASA according to CHADS2 score | CFC to FVIII/FIX levels ≥80% × 5 days then ≥30% × 4 weeks, then as below |
| CHADS2 = 1 to 2 | Consider low-dose ASA (based on factor levels and bleeding risk) | CFC as needed to maintain FVIII/FIX levels ≥10% (ongoing) |
| CHADS2 ≥2 | Warfarin (target INR 2.0–3.0) or new oral anticoagulants preferred over dual antiplatelet therapy (ASA plus clopidogrel). LA appendage occlusion may be preferred in PWH with FVIII/FIX ≤5% to limit duration of antithrombotic therapy | CFC as needed to maintain FVIII/FIX levels ≥30% for duration of antithrombotic therapy |
| IHD5,96 | Stable angina | Low-dose ASA (ongoing) |
| | Unstable angina/NSTEMI | UFH 70 U/kg bolus then 400 U/kg/d × 48 hours, then clopidogrel (600 mg load then 75 mg/d × 4 weeks) + ASA (325 mg load then 80 mg/d long-term) |
| | STEMI >12 hours (PCI not indicated) | As for NSTEMI |
| | <12 hours (PCI indicated) | UFH 70–100 U/kg before PCI, then LMWH 100 U/kg SQ BID × 48 hours; antplatelet therapy after heparin (Figure 2) |
| | PAD with ABI <0.9 | Low-dose ASA OR clopidogrel 75 mg/d (ongoing) |

---

*References are for PWH without inhibitors, unless otherwise specified. Consultation with a hematologist is recommended for all PWH with cardiovascular disease to ensure optimal medical management.

†Long-term ASA prophylaxis may be deferred in individuals with moderate FVIII/FIX deficiency and CHADS2 score <2 to avoid continuous cFC prophylaxis.

‡Bypassing agents should be used in lieu of cFC in PWH with inhibitors as follows: rFVIIIa, 90 mcg/kg every 3–4 hours for 24 hours on the day of PCI and then 90 mcg/kg daily for the 4 weeks of dual antiplatelet therapy or pd-aPCC, 30 units/kg every 12 hours for the first 24 hours followed by the same daily dose for the duration of dual antiplatelet therapy. Use of bypassing agents beyond the first month is discouraged given the risk for thrombogenesis. 6

© 2014 Wolters Kluwer Health, Inc. All rights reserved.
After PCI in PwH, the recommendation is for near-complete \([80\%\text{ or } 40–60\%]\) correction of clotting factor levels for at least 48 hours. This consensus includes factor correction to levels of at least 80% for the first 48 hours followed by daily dosing to a trough level of 30% for the duration of dual antiplatelet therapy. \(^6\) In PwH with inhibitors receiving prolonged antiplatelet therapy, continuous prophylaxis with bypassing agents beyond the first month after PCI risks thrombosis and is not recommended. \(^6\)

Because of the extreme bleeding risk, the use of fibrinolytic therapy in lieu of PCI is contraindicated; however, a recent panel of experts from Europe concluded that fibrinolysis may be justified in PWH when primary PCI is unavailable, provided there is adequate factor correction (minimum of 50% and peak ≥80%) and the capacity for serial measurement of factor levels. \(^6\) When there is 3-vessel CAD or stenosis of the left main coronary artery, surgical coronary artery bypass grafting (CABG) is indicated. \(^6\) In some cases, multivessel PCI provides an alternative in PWH who are deemed too high risk for CABG. \(^6\)

### Other Atherosclerotic Conditions

PWH are susceptible to other atherosclerotic conditions in addition to IHD, although there is very little in the literature describing the presentation and management of additional conditions such as carotid occlusive disease or PAD. In one study, carotid intima media thickness increased significantly in PWH concurrent with the calculated 10-year cardiovascular risk, based on traditional cardiovascular risk factors. \(^6\)

There are currently no descriptions of the medical management of carotid occlusive disease in PWH in the literature. Surgical management is discussed in the next section (“Cardiovascular Conditions Requiring Operations in PWH”).

PWH with cardiovascular risk factors are likely susceptible to PAD as well, encompassing atherosclerosis of the aorta and iliac and lower extremity arteries. A single study from 2000 found that, compared with age- and risk-matched controls, PWH had a significantly lower number of atherosclerotic plaques in the abdominal aorta and leg arteries as detected by color echo Doppler. \(^6\) Nevertheless, similar to IHD, the prevalence of PAD in PWH may be higher than previously believed, because risk factors for the development of PAD are similar to those for CAD. In addition, some evidence suggests that PAD is a marker of other atherosclerosis-related morbidities and mortality. \(^6\) PAD may go unrecognized in PWH for a number of reasons. PWH with severe hemophilic arthropathy may not be sufficiently mobile to manifest claudication, the classic presenting symptom of PAD, \(^6\) because risk factors for the development of PAD are similar to those for CAD. In addition, some evidence suggests that PAD is a marker of other atherosclerosis-related morbidities and mortality. \(^6\) Therefore, PAD is a consideration in PWH with severe arthropathy and cardiovascular risk factors who present with atypical pain or worsening dysfunction of the lower extremities. \(^6\) In addition, PWH should undergo screening for PAD in a manner similar to the general population. \(^6\) Screening for PAD is particularly important in PWH over age 70 and in those under age 50 with a history of smoking or DM.
The ankle-brachial index (ABI), a ratio of upper to lower extremity systolic pressures, assesses the risk of PAD. In PWH with significant joint deformity precluding ABI measurement, a toe-brachial index or duplex ultrasonography are useful options for screening.57 In individuals with an ABI less than 0.9, measures to reduce overall cardiovascular risk should be implemented.52 To reduce the risk for peripheral ischemic events, antiplatelet therapy is typically employed, along with factor replacement as needed to maintain trough FVIII/FIX levels of more than 5% (Table 3).115 However, data supporting the use of antiplatelet therapy in PWH with PAD are limited.115 Individuals with mild hemophilia may tolerate low-dose aspirin without bleeding.55 In contrast, those with moderate or severe hemophilia may require factor correction to avoid bleeding with the use of antiplatelet therapy.57 The use of prophylactic antiplatelet therapy calls for an individualized management approach in consultation with a hematologist. Although pentoxifylline or cilostazol is generally used to manage claudication, the benefits and risk of bleeding attributable to these agents in PWH are unknown; therefore, their use should be discouraged until more information is available.67 Individuals with limb-threatening ischemia (ie, ischemic pain at rest, ischemic ulcers, or gangrene) or with claudication that interferes with quality of life despite pharmacologic treatment are candidates for surgical intervention.

CARDIOVASCULAR CONDITIONS REQUIRING OPERATIONS IN PEOPLE WITH HEMOPHILIA
Numerous cardiovascular conditions, both acquired and congenital, require operations in PWH, including those with inhibitors. An extensive literature search revealed reports of cardiac operations in fewer than 50 PWH (Table 4). With such a small sample, assessment of clinical outcomes in this population is difficult. Results of cardiac procedures in PWH seem similar to those in people without hemophilia, but there is undoubtedly publication bias in these literature reports. A published summary of “best evidence” in this area exists,121 but evidence-based recommendations grounded on controlled trials or even on large observational studies do not exist for PWH undergoing cardiac procedures. Consequently, recommendations for the management of cardiac procedures in PWH come from expert consensus rather than large published series.

General Perioperative Considerations
Table 5 summarizes general recommendations and considerations for surgical management of CVD in PWH. Given the challenges of ensuring hemostasis, particularly when systemic anticoagulation is required, operative intervention is a formidable undertaking in PWH, especially those with inhibitors. Accordingly, less invasive procedures—for example, PCI in lieu of CABG79 or transcatheter correction of cardiac lesions (eg, septal defects,14 patent ductus arteriosus125)—seem preferable whenever possible and appropriate. In PWH for whom elective surgery is the only or best option, preoperative coordination of all necessary personnel and resources is vital. Ample supplies of factor concentrates or bypassing agents and blood products are required. Consultation with a hematologist ideally affiliated with an HTC throughout the perioperative period is paramount.

Cardiac transplantation poses a particular challenge when it comes to coordinating care, because the timing for this procedure cannot be planned in advance. Sufficient supplies of hemostatic agents are essential for this procedure, as is the ability to mobilize emergency laboratory, blood bank, and pharmacy support.115 Not surprisingly, relative to similar procedures in the general population, cardiac operations in PWH incur substantially increased costs (primarily due to hemostatic treatments) and resource utilization.115,123-126 Advance planning and involvement of a multidisciplinary team serves to optimize clinical outcomes while minimizing risk.

Numerous regimens exist for perioperative clotting factor correction. Most reports describe a factor activity level of 100% from immediately before operation extending to the conclusion of the procedure, using bolus dosing or continuous infusion. The latter avoids the fluctuation in factor levels that bolus dosing causes and potentially reduces the total amounts of factor ultimately consumed.51 Consensus suggests that maintaining factor levels in the range of 80–100% of normal activity through the early postoperative period, at least to postoperative day 3, is optimal. Thereafter, standard recommendations endorse maintenance of trough factor levels of 50% until wound healing is nearly complete (postoperative day 10–14).102 In PWH with inhibitors, unless the inhibitor titer is low (≤5 Bethesda units/mL) or there is an opportunity to eradicate the inhibitor before operation, bypassing agents substitute for clotting factor replacement (Table 2).41 In addition to factor replacement therapies, adjunctive use of tranexamic acid for postoperative hemostatic coverage in PWH is an option.58,125 In individuals with refractory bleeding during or after operation, acquired hemostatic perturbations, such as consumptive or dilutional coagulopathies from cardiopulmonary bypass (CPB) or deep hypothermia, are possibilities.127 Cases complicated by acquired coagulopathy may require additional hemostatic products (eg, FFP, platelets) independent of hemophilia factor replacement.

Procedures requiring CPB in PWH constitute high-risk undertakings, given the need for systemic anticoagulation. Consequently, off-pump or minimally invasive variations of procedures that typically require extracorporeal circulatory support, such as CABG,16,98,112 confer less risk to PWH. Ancedotal evidence suggests that minimally invasive procedures reduce the risk for bleeding and coagulopathy in PWH.16,98,112 Published experience with management of anticoagulation and hemostasis during CPB in PWH is limited and entirely anecdotal. Ultimately, this procedure requires a highly individualized approach. In many PWH described in the literature, procedures using CPB incorporated standard heparinization protocols.58,77,105,108,114,116,128 After 100% correction of factor levels by bolus or continuous administration of factor concentrates,57,93,105,110-113,116,118 For 1 patient, the bypass circuit was primed with FFP in lieu of saline to minimize hemo-dilution.51 However, use of this large amount of FFP (as much as 1500 mL) confers additional risk of transfusion-related complications without providing much evidence of benefit.

The monitoring of anticoagulant activity during CPB in PWH is problematic. Activated clotting time (ACT) is most often used to monitor heparin effect. Importantly, the accuracy of ACT monitoring is uncertain unless there are near-normal factor levels.128 In addition, the utility and accuracy of ACT monitoring during CPB when using hemostatic coverage with bypassing agents is uncertain. For monitoring hemostatic therapy during cardiac surgery (with or without CPB), the measurement of PT or factor levels is a viable option. For this purpose, it is necessary to have reliable venous access at a site separate from where factor concentrates will be administered, preferably placed in advance of the operation.109 High heparin concentrations during CPB preclude accurate determination of FVIII levels.105,113 To determine factor levels in this setting, a chromogenic assay with heparin neutralization should be used instead of a coagulation-based assay.109 Point-of-care tests such as thromboelastography monitor perioperative coagulation in settings where hemostatic perturbations are likely (including cardiac operations). However, experience with thromboelastography for directing perioperative hemostatic management specifically in PWH is extremely limited,129 especially in the setting of cardiac surgery. In PWH with factor inhibitors who require bypassing agents for hemostatic coverage, there is no reliable biochemical means of monitoring hemostatic response, other than by clinical parameters.
Table 4. Reports of Cardiac Operations in People With Hemophilia: Survey of the English-Language Literature Between 1980 and 2013

| Reference | Hemophilia Type and Severity | Age (years) | Operation | Inhibitors (Yes/No) | Replacement Therapy | Complications |
|-----------|-------------------------------|-------------|-----------|---------------------|---------------------|---------------|
| Fitzsimons et al (2013) | A (mild, FVIII 8–22%) and IgA deficiency | 53 | Redo-AVR | No | Continuous rFVIII supplemented with intraoperative aminocaproic acid and IgA deficient blood products | Cardiac tamponade |
| Sprunk et al (2012) | A (severe, FVIII <1%) | 38 | 2-v OPCAB | No | Continuous rFVIII supplemented with aminocaproic acid intraoperatively; rFVIII continued until POD 10 | None |
| Kypson et al (2012) | A (severity not specified); HIV positive | 52 | 3-v CABG | No | Continuous plasma-derived FVIII until all wires and lines removed | None |
| Furutachi et al (2012) | A (mild, FVIII = 17–28%) | 61 | Aortic arch replacement (Type A dissection) | No | Continuous rFVIII and tranexamic acid through POD 13 | 32U PRBCs, 50U FFP, and 40 U platelet concentrates given |
| Barillari et al (2012) | A (severe, FVIII <1%) and HCV with liver disease | 58 | 2-v CABG | No | Continuous rFVIII and tranexamic acid through POD 13 | None |
| Zatorska et al (2012) | A (mild, FVIII = 19%) | 30 | MV repair (SBE) | No | Bolus FVIII until POD 7. Warfarin given for 1 month postoperatively | None |
| Lison et al (2011) | A (moderate, FVIII 3–5%) | 67 | 2-v CABG and AVR | No | Minimal FVIII replacement and low dose heparin during CPB; Continuous plasma-derived FVIII used until POD 7 to maintain FVIII level of ~50% | None |
| Frias et al (2011) | A (moderate, FVIII = 8%) | 5 | Biventricular Berlin assist device for 178 days followed by heart transplant complicated by need for 5 days of postoperative ECMO | Yes | Preoperative bolus rFVIII followed by continuous intraoperative and postoperative rFVIII | Developed FVIII inhibitor 2 months after operation |
| Rodriguez et al (2010) | A (severe, FVIII <1%) | 35 weeks | TOF repair | No | Bolus and continuous rFIX until POD 10. Heparin given POD 1–7 | None |
| Kntkow et al (2009) | B (moderate, FIX = 8%) | 61 | AVR bioprosthesis | No | Continuous FIX through POD 12 | Early vein-graft occlusion required PTCA and clopidogrel |
| Pesaro et al (2009) | B (severe, FIX <1%, HIV positive) | 37 | Off-pump 2-v CABG | No | Bolus rFVII through POD 14 and intraoperative and postoperative tranexamic acid | Postoperative GI bleed on LMWH |
| Tang et al (2009) | A (mild, FVIII = 25%) | 60 | AVR (biologic) | No | Bolus rFVIII intraoperatively and postoperatively through POD 13 | None |
| Tang et al (2009) | A (mild, FVIII = 24%) | 72 | Ventricular resection and MV reconstruction | No | Bolus rFVIII intraoperatively and postoperatively through POD 13 | None |
| Tang et al (2009) | A (mild, FVIII = 20%) | 67 | 3-v CABG | No | Bolus rFVIII intraoperatively and postoperatively through POD 11 | None |
| Tang et al (2009) | A (moderate, FVIII = 3%) | 68 | AVR (biologic) and 1-v CABG | No | Bolus rFVIII intraoperatively and postoperatively through POD 24 and perioperative tranexamic acid | None |
| Tang et al (2009) | A (severe, FVIII <1%) | 57 | 4-v CABG | No | Bolus rFVIII intraoperatively and postoperatively through POD 15, intraoperative and postoperative tranexamic acid | None |
| Tang et al (2009) | A (mild, FVIII = 18%) | 61 | AVR and 1-v CABG | No | Bolus rFVIII intraoperatively and postoperatively through POD 15, intraoperative and postoperative tranexamic acid | Atrial flutter |
| Thankachen et al (2007) | B (mild, FIX = 14%) | 25 | AVR, MVR (mechanical [Starr Edwards]) | No | Bolus plasma-derived FIX preoperatively and continuous infusion postoperatively to maintain FIX levels 80% of normal POD 1–3, then tapered. INR maintained between 1.5 and 2.0 | Postoperative cardiac tamponade on POD 4, ARF |
| Gasparović et al (2007) | A (severe, FVIII <1.0%) | 47 | AVR (bioprosthesis) | No | Bolus followed by continuous infusion of FVIII along with intraoperative aprotinin. Continuous FVIII continued until POD 12 | None |
| Munugan et al (2006) | A (mild, FVIII = 11%) | 5 weeks | Repair TAPVR | No | Continuous rFVIII until POD 8 | None |
| Munugan et al (2006) | A (moderate, FVIII = 5%) | 11 weeks | Repair VSD and TAPVR | No | Continuous rFVIII until POD 11 | None |

(Continued)
| Reference | Hemophilia Type and Severity | Age (years) | Operation                | Inhibitors (Yes/No) | Replacement Therapy                          | Complications                                           |
|-----------|-----------------------------|-------------|--------------------------|---------------------|---------------------------------------------|---------------------------------------------------------|
| Eren et al (2006) | A (severe, FVIII <1%) | 62 | 3-v CABG | No | Bolus rFVIII given during operation along with 8 U FFP, 8 U platelet concentrates, and 7 U PRBCs. Bolus rFVIII given postoperatively through POD 7. | None                                                   |
| Stine and Becton (2006) | A (mild, FVIII = 6%) | 64 | 1-v CABG and MV repair | No | Continuous FVIII until POD 3, then bolus FVIII for 7 days. Maintained on aspirin and warfarin for 1 month after operation. | None                                                   |
| Grandmougin et al (2005) | (severe, FIX <1%) and HCV | 52 | OPCAB x 2 | No | Bolus and continuous plasma derived FIX until POD 14 | None                                                   |
| De Bels et al (2004) | A (mild, FVIII = 10%) | 53 | 3-v CABG | No | Preoperative bolus of plasma-derived FVIII combined with intraoperative continuous FVIII infusion and tranexamic acid. FVIII infusion stopped on POD 3. | Postoperative bleeding. Chest tube drainage increased (1590 mL). Transfusion of 6 U PRBCs, 4 U FFP, and 6 platelet packs. |
| Kaminishi et al (2003) | A (mild, FVIII = 6.9%) | 53 | Heart transplant | No | Bolus plasma-derived FVIII continued until POD 6. High-dose plasma-derived FVIII supplemented with rFVIIa on POD 6 after anamnesis developed. | Seizure on POD 2 (watershed injury on MRI). Bacteremia on POD 6. Bleeding on POD 7 requiring epsilon aminocaproic acid. Maintained on rFVIIa. |
| Sheth et al (2001) | A (severe, FVIII <1%) | 14 | Aortic root replacement | Yes | | | |
| MacKinlay et al (2000) | #117 | A (mild, FVIII = 15%) | 56 | 2-v CABG | No | Continuous plasma-derived FVIII until POD 9 | None |
| MacKinlay et al (2000) | #217 | A (mild, FVIII = 25%) | 56 | 5-v CABG | No | Bolus plasma-derived FVIII until POD 10 | None |
| MacKinlay et al (2000) | #317 | A (moderate, FVIII = 4%) | 49 | AVR and MVR | No | Bolus plasma-derived FVIII until POD 16 | None |
| MacKinlay et al (2000) | #417 | A (moderate, FVIII = 4%) | 54 | Redo AVR and MVR | No | Bolus plasma-derived FVIII until POD 15 | None |
| MacKinlay et al (2000) | #517 | A (mild, FVIII = 7%) | 58 | AVR | No | Continuous plasma-derived FVIII until POD 9 | Warfarin given for mechanical valve |
| Donahue et al (1999) | B (mild, FIX = 32%) | 80 | ASD closure | No | | | Drainage of postoperative pericardial effusion |
| Palanzo and Sadr (1995) | B (mild, FIX = 8%) | 71 | 3-v CABG | No | | | Aortic dissection POD 2, emergency reoperation, perioperative death |
| Scharfman et al (1993) | B (moderate, FIX = 2.4%) | 52 | 4-v CABG | No | Bolus FIX intraoperatively and postoperatively. Perioperative tranexamic acid. Bolus plasma-derived FIX daily until discharge (POD 6). Aprotinin used perioperatively. | None |
| Wilson et al (1991) | B (mild, FIX = 12%) | 74 | CAGB | No | | | None |
| Mazzucco et al (1986) | B (severe, FIX <1%) | 7 | VSD and AV repair | No | | Perioperative PIC and FFP until POD 20 | None |
| Raish et al (1985) | B (moderate, FIX = 5%) | 59 | 4-v CAGB | No | | | None |
| Roskos et al (1983) | B (moderate, FIX = 2%) | 16 | TGA, VSD and pulmonic stenosis repair | No | | | None |
| Roskos et al (1983) | A (severe, FVIII <1%) | 74 | TGA repair | No | Bolus cryoprecipitate until POD 10 | None |

1-v CAGB indicates 1-vessel coronary artery bypass grafting; 2-v CAGB, 2-vessel coronary artery bypass grafting; 3-v CAGB, 3-vessel coronary artery bypass grafting; 4-v CAGB, 4-vessel coronary artery bypass grafting; 5-v CAGB, 5-vessel coronary artery bypass grafting; 6-v CAGB, 6-vessel coronary artery bypass grafting; 2-v OPCAB, 2-vessel off-pump coronary artery bypass; ARF, acute renal failure; ASD, atrial septal defect; AV atrial valve; AVR, aortic valve replacement; Bi-VAD, biventricular assist device; CPB, cardiopulmonary bypass; ECMO, extracorporeal membrane oxygenation; FFP, fresh frozen plasma; FIX, factor IX; FVIII, factor VIII; GI, gastrointestinal; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IgA, immunoglobulin A; INR, international normalized ratio; LMWH, low-molecular-weight heparin; MI, myocardial infarction; MRI, magnetic resonance imaging; MV, mitral valve; MVR, mitral valve replacement; OPCAB, off-pump coronary artery bypass; PCC, prothrombin complex concentrate; pd-pCC, plasma-derived activated prothrombin complex concentrate; POD, postoperative day; PRBCs, packed red blood cells; PTCA, percutaneous transluminal coronary angioplasty; rFIX, recombinant factor IX; rFVIIa, recombinant activated factor VII; rFVIII, recombinant factor VIII; SBE, subacute bacterial endocarditis; TAPVR, total anomalous pulmonary venous return; TGA, transposition of the great arteries; TOF, tetralogy of Fallot; VSD, ventricular septal defect. 

Table 4. (Continued)
Table 5. Management Consensus for People With Hemophilia Requiring Surgical Treatment of Cardiovascular Disease

| Without Factor VIII or Factor IX Inhibitors | With Factor Inhibitors |
|------------------------------------------|------------------------|
| Preoperative assessment                   |                        |
| • Measure factor levels                  | • Enlist multidisciplinary team (HTC, if possible) |
| • Enlist multidisciplinary team (HTC, if possible) |
| • Assess for inhibitors (inhibitor titer by Bethesda assay) |
| Intraoperative treatment of PWH having cardiac operations |                        |
| • Continuous or bolus CFC to maintain levels above 80% at end of operation | • Bypassing agents after completion of CPB |
| • Antifibrinolytics during operation     | • Dosing of bypassing agents is purely empiric without good guidelines |
| • Minimally invasive, if possible        | • Antifibrinolytic agents during and shortly after CPB |
| • Tissue valve preferred for valve replacements | • Use bolus or continuous factor replacement in patients with low levels of inhibitors (<5 BU/ml) |
| • Low dose of heparin to match defect in intrinsic clotting cascade |                        |
| • Multifactorial blood conservation program that includes cell salvage, mini-circuits, microplegia, and ultrafiltration |                        |
| • Assay for factor levels on CPB (chromogenic assay) |                        |
| • Factor levels above 80% in early postoperative period |                        |
| Postoperative care of PWH after cardiac operations |                        |
| • Continuous or bolus factor replacement (preferably with recombinant products) for 7–10 days | • Bypassing agents at higher doses for 3 days after operation |
| • Factor level replacement to above 50% after POD 3 | • Bypassing agents at reduced level for 7–10 days after operation |
| • Anticoagulation (eg, LMWH) necessary to avoid thrombosis as long as supplemental high-level factor replacement is given | • Anticoagulation during the period of use of bypassing agents |
| • Warfarin for 3 months after valve replacement but with supplemental factor replacement to maintain levels above 5% |                        |
| • Low-dose aspirin prophylaxis for life |                        |
| • Screen for inhibitor development 1–2 months after operation |                        |
| BU indicates Bethesda unit; CFC, clotting factor correction; CPB, cardiopulmonary bypass; HTC, hemophilia treatment center; LMWH, low-molecular-weight heparin; POD, postoperative day; PWH, people with hemophilia.

Valve Replacement

There are several important considerations specific to PWH undergoing valve replacement, including the need for postoperative anticoagulation. In the majority of PWH undergoing valve replacement, a bioprosthetic valve is preferred to avoid the need for prolonged anticoagulation.107–109 Published reports suggest that anticoagulation strategies in the immediate postoperative period vary and include LMWH for a period of up to approximately 10 days,6,58,106,107 warfarin,77 or no therapy.77,109 Specific institutional recommendations for anticoagulation from centers in Italy and the Netherlands advocate the use of LMWH (5000–7000 U twice daily) for 10 days after valve replacement, in conjunction with factor replacement.6 Subsequently, in those who receive bioprosthetic valves, warfarin derivatives targeting an INR of 2.5–3.5 are recommended for a period of 3 months, during which time trough factor levels should be maintained at ≥5%.6 In certain cases, based on age or hemodynamics,67 PWH may receive a mechanical prosthesis because of hypothetical superior longevity. Use of a mechanical valve mandates indefinite anticoagulation and maintenance of factor levels above 30% by continuous prophylaxis.88 One case report, however, described the initial deferment of anticoagulation after mechanical valve replacement in a man with moderate hemophilia A who developed FVIII inhibitors.130 Instead, measurement of D-dimer levels and monitoring of echocardiography eventually pointed to evidence of thrombosis and prompted warfarin therapy.130 Experience with anuloplasty in this population is very limited, with only 2 case reports identified in the literature.102,111 Individuals without hemophilia who undergo anuloplasty typically receive anticoagulation for 3 months after the procedure, similar to those undergoing bioprosthetic valve replacement.102 Whether PWH require similar anticoagulation after anuloplasty is uncertain.

Lower Extremity Peripheral Arterial Disease

To date, there is only a single description of surgical intervention for PAD in the setting of hemophilia: a 61-year-old man with mild hemophilia A who underwent femoral-popliteal bypass using an autogenous saphenous vein graft.113 The patient received hemostatic coverage with intermittent boluses of plasma-derived FVIII. Other details of the procedure are lacking. Stenting is a possible option in PWH who have aortoiliac disease.112 However, the benefits of this approach in PWH are uncertain, especially in view of the need for ongoing antiplatelet or antithrombotic therapy.57

Acquired Aortic Conditions

A few cases of elective repair of abdominal aortic aneurysm in PWH appear in the literature. These aneurysms had the gross and histologic appearance of typical atherosclerotic aneurysms. Two patients with mild133 and moderate134 hemophilia A had surgical graft replacement; 1 had a collagen-coated Dacron bifurcation graft placed to avoid the need for preclotting.133 More recently, a man with severe hemophilia B had endovascular aneurysm repair (EVAR).135 All individuals met the criteria for elective repair, based on aneurysm size or on a rapid increase in diameter.136 In all cases, factor levels were corrected to ≥100% of normal for the operation using corresponding factor concentrates, followed by maintenance of factor levels at 80–100% for approximately 1 week after the procedure.135–137 Intraoperative heparinization was employed in 2 cases.134,135 In individuals without bleeding disorders, blood loss and transfusion requirements are significantly reduced for EVAR compared with open procedures.135 Whereas logic supports the use of minimally invasive procedures such as EVAR in PWH,135 given the existence of only a single reported case of EVAR in PWH, it is difficult to generalize this recommendation to the entire population.

Literature reports describe the surgical management of aortic dissection in PWH.100,116,127,137 Because emergent intervention is necessary, the management of acute aortic dissection poses challenges beyond those of elective cardiovascular procedures in PWH. Surgical and other considerations are summarized in a recently published first-ever case report describing management of an acute type A dissection in an individual with hemophilia A.127

Carotid Occlusive Disease

Two reports document carotid endarterectomy after cerebrovascular events in a total of 3 PWH: 1 with mild hemophilia B;136 1 with...
moderate hemophilia B, and 1 with mild hemophilia A. Two of these individuals had substantial cardiovascular risk factors, and 1 had prior CABG. These reports did not provide extensive operative details. Management of hemophilia factor replacement involved continuous intraoperative infusion of recombinant FIX in both individuals with hemophilia B, in 1 case continuing for 48 hours postprocedure. In the other case, postoperative FIX replacement was achieved by bolus dosing continued for 7 days after operation. Ironically, both individuals with hemophilia B developed carotid artery pseudotumors within 8 weeks of endarterectomy, and both underwent successful excision of their pseudotumors under FIX cover. The individual with hemophilia A received bolus dosing of FVIII during endarterectomy and for 10 days thereafter. A Dacron patch was used for carotid closure in 1 of the men with hemophilia B.

CONCLUSIONS

As the population of PWH ages, cardiovascular health care providers will encounter increasing numbers of PWH presenting with typical age-related cardiovascular conditions, in addition to other acquired or congenital conditions spanning all ages. The management of cardiovascular conditions in PWH may prove especially challenging when antithrombotic therapy or surgical intervention is indicated, particularly in the presence of inhibitors. Further complicating the challenges of ensuring hemostasis in PWH is the lack of evidence-based guidelines upon which to base therapeutic decisions. Accordingly, current recommendations for the medical and surgical management of common cardiovascular conditions in PWH derive from anecdotal experience and expert opinion. Most recommendations reflect guidelines and common practices for people without hemophilia. Ultimately, the rigorous, systematic investigation of management strategies for many cardiovascular conditions is unobtainable, given the relative rarity of hemophilia and even smaller numbers of PWH with any given cardiovascular condition. The utilization of data from existing global registries or from newly created registries may provide useful information regarding approaches to antithrombotic and hemostatic therapy in PWH. In the meantime, the best options include individualization of treatment protocols, with coordinated input from a multidisciplinary team. To optimize resource utilization and clinical outcome and to minimize bleeding risk and complications, close consultation with a hematologist, ideally in association with an HTC, is essential.

ACKNOWLEDGMENTS

Writing assistance was provided by Lara Primak, MD, of ETHOS Health Communications in Newtown, Pennsylvania, with financial support from Novo Nordisk Inc., in compliance with international Good Publication Practice guidelines.

REFERENCES

1. Boggio LN, Kessler CM. Hemophilia A and B. In: Kitchens CS, Alving BM, Kessler CM, eds. Consultative Hemostasis and Thrombosis. 2nd ed. Philadelphia: Elsevier Health Sciences; 2007:45–59.
2. Kulkarni R, Soucie JM. Pediatric hemophilia: a review. Semin Thromb Hemost. 2007;33:645–652.
3. DiMichele DM. Inhibitors in Hemophilia: A Primer. 4th ed. Montreal: World Federation of Hemophilia; 2008.
4. Bolton-Maggs PH, Pasi KJ. Haemophilia A and B. Lancet. 2003;361:1801–1809.
5. Goedert JJ, Eyster ME, Lederman MM, et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood. 2002;102:1547–1550.
6. Mannucci PM, Mauser-Bunschoten EP. Cardiovascular disease in haemophilia patients: a contemporary issue. Haemophilia. 2010;16(suppl 3):S8–S6.
7. Plug I, Van Der Bom JG, Peters M, et al. Mortality and causes of death in patients with hemophilia, 1992–2001: a prospective cohort study. J Thromb Haemost. 2006;4:510–516.
8. Darby SC, Keeling DM, Spooner RJ, et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effects on subsequent mortality. 1977–99. J Thromb Haemost. 2004;2:1047–1054.
9. Goel R, Krishnamurti L. Mortality, health care utilization and associated diagnoses in hospitalized patients with haemophilia in the United States: first reported nationwide estimates. Haemophilia. 2012;18:668–692.
10. Darby SC, Kan SW, Spooner RJ, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood. 2007;110:815–825.
11. Triemstra M, Rosendaal FR, Smit C, et al. Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med. 1995;123:823–827.
12. Ragni MV. Aging in haemophilia: getting to the heart of the matter. Thromb Haemost. 2011;105:207–208.
13. Srinvakes, Reiber, G., Gerrits, W., et al. Decreased coagulability has no clinically relevant effect on atherogenesis: observations in individuals with a hereditary bleeding tendency. Circulation. 2001;104:762–767.
14. Bierre-Rafi S, Tuenenburg A, Haak BW, et al. Factor VIII deficiency does not protect against atherosclerosis. J Thromb Haemost. 2012;10:30–37.
15. Tuenenburg A, Rutten A, Kavousi M, et al. Coronary artery calcification in hemophilia A: no evidence for a protective effect of factor VIII deficiency on atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:799–804.
16. Foley CJ, Nichols L, Jeong K, et al. Coronary atherosclerosis and cardiovascular mortality in hemophilia. J Thromb Haemost. 2010;8:208–211.
17. Zwiers M, Lefrandt JD, Mulder D, et al. Coronary artery calcification score and carotid intima–media thickness in patients with hemophilia. J Thromb Haemost. 2012;10:23–29.
18. Kulkarni R, Soucie JM, Evatt BL; Hemophilia Surveillance System Project Investigators. Prevalence and risk factors for heart disease among males with hemophilia. Am J Hematol. 2005;79:36–42.
19. Ragni MV, Moore CG. Atherosclerotic heart disease: prevalence and risk factors in hospitalized men with haemophilia A. Haemophilia. 2011;17:867–871.
20. Alsulaiman MM, Chang K, Arjomand H, et al. Acute left anterior descending artery occlusion in a haemophiliac A Patient during recombinant factor VIII infusion: treatment with coronary angioplasty. Catheter Cardiovasc Interv. 2000;50:468–472.
21. Girolami A, Ruzzon E, Fabris F, et al. Myocardial infarction and other arterial occlusions in hemophilia a patients. A cardiological evaluation of all 42 cases reported in the literature. Acta Haemol. 2006;116:120–125.
22. Marresca L, Giallauria F, D’Agostino MA, et al. A severe haemophiliac patient with acute coronary syndrome admitted to cardiac rehabilitation. Haemophilia. 2012;18:e45–e47.
23. Bovenzi F, De Luca L, Signore N, et al. Abciximab for the treatment of an acute thrombotic coronary occlusion during stent implantation in a patient with severe hemophilia B. Ital Heart J. 2003;4:728–730.
24. Biere-Rafi S, Baarslag MA, Peters M, et al. Cardiovascular risk assessment in haemophilia patients. Thromb Haemost. 2011;105:274–278.
25. Fransen van de Putte DE, Fischer K, Makris M, et al. Increased prevalence of hypertension in haemophilia patients. Thromb Haemost. 2012;108:750–757.
26. Lim MY, Pruthi RK. Cardiovascular disease risk factors: prevalence and management in adult hemophilia patients. Blood Coagul Fibrinolysis. 2011;22:402–406.
27. Konkle BA, Kessler C, Aleddor L, et al. Emerging clinical concerns in the aging haemophilia patient. Haemophilia. 2009;15:1197–1209.
28. Fransen van de Putte DE, Fischer K, Makris M, et al. Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients. Thromb Haemost. 2013;109:16–23.
29. Sharathkumar MM, Soucie JM, Trawinski B, et al. Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US). Haemophilia. 2011;17:597–604.
30. Friis-Møller N, Pasi KJ, Sabin CA, et al; DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723–1735.
31. Jacob AJ, Sutherland GR, Boon NA, et al. Dilated cardiomyopathy in haemophiliacs infected with the human immunodeficiency virus. Scot Med J. 1993;38:112–113.
32. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535–544.
33. MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders. National Hemophilia Foundation website. Available at: http://www.hemophilia.org/NHFWebMainPgs/MainNHF.aspx?menuid=57&contentid=693. Updated 2013. Accessed October 5, 2013.

34. Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors’ Organization (UKHDCO) guideline approved by the British Committee for Standards in Haematology. Haemophilia. 2008;14:671–684.

35. Franchini M. The modern treatment of haemophilia: a narrative review. Blood Transfus. 2013;11:178–182.

36. Pesaro AE, Gav M, Carbone R, et al. Coronary artery bypass surgery, angiplasty and long term anti-plaetlet treatment in a type B haemophilia patient. Clinics (Sao Paulo). 2009;64:822–823.

37. Hermans C, Brackmann HH, Schinco P, et al. The case for wider use of recombinant factor VIII concentrates. Crit Rev Oncol Hematol. 2012;83:11–20.

38. Ludlam CA, Powderly WG, Bozzette S, et al. Clinical perspectives of emerging pathologies in bleeding disorders. Lancet. 2006;367:252–261.

39. Kim DK, Kim DI, Kim MS, et al. Successful percutaneous coronary intervention for acute coronary syndrome in a patient with severe hemophilia A. Korean Circ J. 2010;40:527–529.

40. Kempton CL, White GC 2nd. How to treat a haemophilia A patient with a factor VIII inhibitor. Br J Haematol. 2008;141:11–17.

41. Kulkarni R. Comprehensive care of the patient with haemophilia and inhibitors undergoing surgery: practical aspects. Haemophilia. 2013;19:2–10.

42. Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost. 2012;10:1478–1485.

43. Chavin SI, Siegel DM, Rocco TA Jr, et al. Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor. Am J Med. 1988;85:245–249.

44. Fukushima H, Fujimura Y, Takahashi Y, et al. Laboratory evidence of DIC under FEIBA treatment of a hemophilic patient with intracranial bleeding and high titre factor VIII inhibitor. Thromb Res. 1981;22:177–184.

45. Schimpf K, Zeltsch C, Zeltsch P. Myocardial infarction complicating activated prothrombin complex concentrate substitution in patient with haemophilia A. Lancet. 1982;2:1043.

46. Ehrlich H. Henzel MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia. 2002;8:83–90.

47. NovoSeven RT (Coagulation Factor VIIa [Recombinant], Room Temperature Stable) [prescribing information]. Bagsvaerd, Denmark: Novo Nordisk A/S; 2014.

48. Hardy JF, Bélisle S, van der Linden P. Efficacy and safety of recombinant activated factor VII in patients with congenital bleeding disorders: a single center experience and nationwide cohort study. BMJ. 2011;342:d124.

49. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–2870.

50. You JJ, Singer DE, Howard PA, et al. American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):e51S–e575S.

51. Kalscheur JS. Pharmacologic interventions for reversing the effects of oral anticoagulants. Am J Health Syst Pharm. 2003;71(10 suppl):S12–S21.

52. Tripodi A, Palareti G. New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation. J Intern Med. 2009;272:554–565.

53. Cheung VT, Hunter RI, Ginks MR, et al. Management of thromboembolic risk in persons with haemophilia and atrial fibrillation: is left atrial appendage occlusion the answer for those at high risk? Haemophilia. 2013;19:684–686.

54. Cid AR, Zorio E, Haya S, et al. Treatment in a haemophilic A patient with paroxysmal atrial fibrillation and ischemic heart disease. Haemophilia. 2007;13:760–762.

55. DeWitt ES, DiMichele DM, Larsen K, et al. Successful cryoablation of atrioventricular nodal reentrant tachycardia in a child with hemophilia A. J Pediatr Hematol Oncol. 2010;32:404–406.

56. MacKinlay N, Taper J, Renisson F, et al. Cardiac surgery and catheterization in patients with haemophilia. Haemophilia. 2000;6:84–88.

57. Lim MY, Pruthi RK. Impact of lifestyle modification on symptomatic coronary artery disease in a haemophilia patient with inhibitors. Haemophilia. 2011;17:e1006–e1007.

58. Guo Y, Zhang X, Huang D, et al. Acute myocardial infarction in a Chinese patient with haemophilia A and risk factors for coronary artery disease: a case report with autopsy. Haemophilia. 2010;16:691–693.

59. Lim MY, Pruthi RK. Outcomes of management of acute coronary syndrome in patients with congenital bleeding disorders: a single center experience and review of the literature. Thromb Res. 2012;130:316–322.

60. Ferraro C, Renders F, Cairoli A, et al. Management of an acute coronary syndrome in a patient with severe haemophilia A. Haemophilia. 2007;13:763–765.

61. Coppola A, Tagliaferri A, Franchini M. The management of cardiovascular diseases in patients with hemophilia. Semin Thromb Hemost. 2010;36:91–102.

62. Fiebinger P, Gnant S, Labrezky A, et al. Percutaneous coronary intervention in patients with haemophilia presenting with acute coronary syndrome: an interventional dilemma: case series, review of the literature, and tips for management. J Thromb Thrombolysis. 2013;35:271–278.
autologous factor VIII after switching to third generation recombinant product. *Blood (ASH Annual Meeting Abstracts)*. 2005;106:4060.

132. Olin JW, Sealove BA. Peripheral artery disease: current insight into the disease and its diagnosis and management. *Mayo Clin Proc*. 2010;85:678–692.

133. Bergqvist D, Thimberg L, Bergentz SE, et al. Abdominal aortic aneurysm surgery in a hemophiliac. *Vasa*. 1985;14:394–397.

134. Kobayashi M, Matsushita M, Nishikimi N, et al. Treatment for abdominal aortic aneurysm in a patient with hemophilia A: a case report and review of the literature. *J Vasc Surg*. 1997;25:945–948.

135. Marrocco-Trischitta MM, Melisano G, Castellano R, et al. Endovascular abdominal aortic aneurysm repair in a patient with severe hemophilia B. *J Endovasc Ther*. 2009;16:120–123.

136. Brewster DC, Cronenwett JL, Hallett JW Jr, et al; Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. Guidelines for the treatment of abdominal aortic aneurysms. Report of a subcommittee of the Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. *J Vasc Surg*. 2003;37:1106–1117.

137. Chun PK, Flannery EP, Bowen TE. Open-heart surgery in patients with hematologic disorders. *Am Heart J*. 1983;105:835–842.

138. Bowles L, Yee TT. Carotid endarterectomy in 2 patients with hemophilia. *Haemophilia*. 2012;18:4.

139. Malam Y, Tsui J, Sheikh SE, et al. Journal rubric. Haemophilic pseudotumour of the carotid artery. *Vasc Med*. 2012;17:193–194.